Xuanzhu Bio-B Shares Surge Over 8% on NG-350A Phase 1b FORTRESS Study Preliminary Results Presentation at 2026 AACR

Stock News04-23

Xuanzhu Bio-B (02575) saw its shares rise more than 8% during the trading session. As of the time of writing, the stock had climbed 8.65% to HK$28.4, with a turnover of HK$119 million.

On April 20, Xuanzhu Bio-B announced that preliminary results from the NG-350A Phase 1b FORTRESS study will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting on April 20, 2026.

NG-350A is an oncolytic immunotherapy drug intended for the treatment of mismatch repair proficient (pMMR) locally advanced rectal cancer (LARC). The drug was licensed by the group from Akamis Bio, Inc., a clinical-stage oncology company focused on raising the standard of care for colorectal cancer.

The Phase 1b FORTRESS study (NCT06459869) is an open-label, single-arm, multicenter clinical trial designed to evaluate NG-350A in combination with chemoradiotherapy (CRT) for the treatment of adult patients with pMMR LARC. Eligible patients must have at least one risk factor for local or distant recurrence, or present with oligometastatic disease.

The ongoing study aims to assess the antitumor effects of NG-350A plus chemoradiotherapy after 12 weeks of active treatment. Its goal is to determine whether NG-350A can increase the composite response rate—defined as the proportion of patients achieving clinical complete response (cCR) or near clinical complete response (ncCR)—compared to chemoradiotherapy alone in patients with pMMR locally advanced rectal cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1174006676?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 11:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174006676","market":"sg","top_or_hot":-1,"title":"Xuanzhu Bio-B Shares Surge Over 8% on NG-350A Phase 1b FORTRESS Study Preliminary Results Presentation at 2026 AACR","media":"Stock News","content":"<p>Xuanzhu Bio-B (02575) saw its shares rise more than 8% during the trading session. As of the time of writing, the stock had climbed 8.65% to HK$28.4, with a turnover of HK$119 million.</p>\n<p>On April 20, Xuanzhu Bio-B announced that preliminary results from the NG-350A Phase 1b FORTRESS study will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting on April 20, 2026.</p>\n<p>NG-350A is an oncolytic immunotherapy drug intended for the treatment of mismatch repair proficient (pMMR) locally advanced rectal cancer (LARC). The drug was licensed by the group from Akamis Bio, Inc., a clinical-stage oncology company focused on raising the standard of care for colorectal cancer.</p>\n<p>The Phase 1b FORTRESS study (NCT06459869) is an open-label, single-arm, multicenter clinical trial designed to evaluate NG-350A in combination with chemoradiotherapy (CRT) for the treatment of adult patients with pMMR LARC. Eligible patients must have at least one risk factor for local or distant recurrence, or present with oligometastatic disease.</p>\n<p>The ongoing study aims to assess the antitumor effects of NG-350A plus chemoradiotherapy after 12 weeks of active treatment. Its goal is to determine whether NG-350A can increase the composite response rate—defined as the proportion of patients achieving clinical complete response (cCR) or near clinical complete response (ncCR)—compared to chemoradiotherapy alone in patients with pMMR locally advanced rectal cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xuanzhu Bio-B Shares Surge Over 8% on NG-350A Phase 1b FORTRESS Study Preliminary Results Presentation at 2026 AACR</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXuanzhu Bio-B Shares Surge Over 8% on NG-350A Phase 1b FORTRESS Study Preliminary Results Presentation at 2026 AACR\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-23 11:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Xuanzhu Bio-B (02575) saw its shares rise more than 8% during the trading session. As of the time of writing, the stock had climbed 8.65% to HK$28.4, with a turnover of HK$119 million.</p>\n<p>On April 20, Xuanzhu Bio-B announced that preliminary results from the NG-350A Phase 1b FORTRESS study will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting on April 20, 2026.</p>\n<p>NG-350A is an oncolytic immunotherapy drug intended for the treatment of mismatch repair proficient (pMMR) locally advanced rectal cancer (LARC). The drug was licensed by the group from Akamis Bio, Inc., a clinical-stage oncology company focused on raising the standard of care for colorectal cancer.</p>\n<p>The Phase 1b FORTRESS study (NCT06459869) is an open-label, single-arm, multicenter clinical trial designed to evaluate NG-350A in combination with chemoradiotherapy (CRT) for the treatment of adult patients with pMMR LARC. Eligible patients must have at least one risk factor for local or distant recurrence, or present with oligometastatic disease.</p>\n<p>The ongoing study aims to assess the antitumor effects of NG-350A plus chemoradiotherapy after 12 weeks of active treatment. Its goal is to determine whether NG-350A can increase the composite response rate—defined as the proportion of patients achieving clinical complete response (cCR) or near clinical complete response (ncCR)—compared to chemoradiotherapy alone in patients with pMMR locally advanced rectal cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1174006676","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174006676","pubTimestamp":1776913837,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Xuanzhu Bio-B (02575) saw its shares rise more than 8% during the trading session. As of the time of writing, the stock had climbed 8.65% to HK$28.4, with a turnover of HK$119 million. On April 20,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK4585":"ETF&股票定投概念","BK4017":"黄金","VXUS":"国际股票ETF-Vanguard","02575":"轩竹生物-B","NG":"NovaGold Resources Inc","BK4588":"碎股"},"translate_title":"NG-350A 1B期FORTRESS研究初步结果在2026年AACR上公布，轩竹生物-B股价飙升超过8%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02575":1,"VXUS":1,"NG":1},"content_text":"Xuanzhu Bio-B (02575) saw its shares rise more than 8% during the trading session. As of the time of writing, the stock had climbed 8.65% to HK$28.4, with a turnover of HK$119 million.\nOn April 20, Xuanzhu Bio-B announced that preliminary results from the NG-350A Phase 1b FORTRESS study will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting on April 20, 2026.\nNG-350A is an oncolytic immunotherapy drug intended for the treatment of mismatch repair proficient (pMMR) locally advanced rectal cancer (LARC). The drug was licensed by the group from Akamis Bio, Inc., a clinical-stage oncology company focused on raising the standard of care for colorectal cancer.\nThe Phase 1b FORTRESS study (NCT06459869) is an open-label, single-arm, multicenter clinical trial designed to evaluate NG-350A in combination with chemoradiotherapy (CRT) for the treatment of adult patients with pMMR LARC. Eligible patients must have at least one risk factor for local or distant recurrence, or present with oligometastatic disease.\nThe ongoing study aims to assess the antitumor effects of NG-350A plus chemoradiotherapy after 12 weeks of active treatment. Its goal is to determine whether NG-350A can increase the composite response rate—defined as the proportion of patients achieving clinical complete response (cCR) or near clinical complete response (ncCR)—compared to chemoradiotherapy alone in patients with pMMR locally advanced rectal cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1174006676","isCrawlerRequest":true}